Selective Inhibition of HDAC1 and HDAC2 as a Potential Therapeutic Option for B-ALL

Purpose: Histone deacetylase inhibitors (HDACi) have recently emerged as efficacious therapies that target epigenetic mechanisms in hematologic malignancies. One such hematologic malignancy, B-cell acute lymphoblastic leukemia (B-ALL), may be highly dependent on epigenetic regulation for leukemia development and maintenance, and thus sensitive to small-molecule inhibitors that target epigenetic mechanisms. Experimental Design: A panel of B-ALL cell lines was tested for sensitivity to HDACi with varying isoform sensitivity. Isoform-specific shRNAs were used as further validation of HDACs as relevant therapeutic targets in B-ALL. Mouse xenografts of B-cell malignancy–derived cell lines and a pediatric B-ALL were used to demonstrate pharmacologic efficacy. Results: Nonselective HDAC inhibitors were cytotoxic to a panel of B-ALL cell lines as well as to xenografted human leukemia patient samples. Assessment of isoform-specific HDACi indicated that targeting HDAC1-3 with class I HDAC-specific inhibitors was sufficient to inhibit growth of B-ALL cell lines. Furthermore, shRNA-mediated knockdown of HDAC1 or HDAC2 resulted in growth inhibition in these cells. We then assessed a compound that specifically inhibits only HDAC1 and HDAC2. This compound suppressed growth and induced apoptosis in B-ALL cell lines in vitro and in vivo, whereas it was far less effective against other B-cell–derived malignancies. Conclusions: Here, we show that HDAC inhibitors are a potential therapeutic option for B-ALL, and that a more specific inhibitor of HDAC1 and HDAC2 could be therapeutically useful for patients with B-ALL. Clin Cancer Res; 21(10); 2348–58. ©2015 AACR.

[1]  F. A. Schroeder,et al.  A Selective HDAC 1/2 Inhibitor Modulates Chromatin and Gene Expression in Brain and Alters Mouse Behavior in Two Mood-Related Tests , 2013, PloS one.

[2]  J. Cigudosa,et al.  Preclinical activity of LBH589 alone or in combination with chemotherapy in a xenogeneic mouse model of human acute lymphoblastic leukemia , 2011, Leukemia.

[3]  R. Stam,et al.  Connectivity mapping identifies HDAC inhibitors for the treatment of t(4;11)-positive infant acute lymphoblastic leukemia , 2012, Leukemia.

[4]  T. Katoh,et al.  Involvement of p21waf1/cip1 expression in the cytotoxicity of the potent histone deacetylase inhibitor spiruchostatin B towards susceptible NALM-6 human B cell leukemia cells. , 2011, International journal of oncology.

[5]  Yonghong Xiao,et al.  Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. , 2011, Cancer cell.

[6]  C. So,et al.  Transcriptional and epigenetic networks in haematological malignancy , 2011, FEBS letters.

[7]  F. Lombardo,et al.  Optimization of the in vitro cardiac safety of hydroxamate-based histone deacetylase inhibitors. , 2011, Journal of medicinal chemistry.

[8]  M. Esteller,et al.  Cancer epigenetics reaches mainstream oncology , 2011, Nature Medicine.

[9]  S. Minucci,et al.  HDACs link the DNA damage response, processing of double-strand breaks and autophagy , 2011, Nature.

[10]  P. Grandi,et al.  Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes , 2011, Nature Biotechnology.

[11]  Andrew J. Wilson,et al.  Hdac3 is essential for the maintenance of chromatin structure and genome stability. , 2010, Cancer cell.

[12]  S. Jackson,et al.  Human HDAC1 and HDAC2 function in the DNA-damage response to promote DNA nonhomologous end-joining , 2010, Nature Structural &Molecular Biology.

[13]  Steven S. Foster,et al.  Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair , 2010, Proceedings of the National Academy of Sciences.

[14]  M. Hedayati,et al.  Downregulation of Homologous Recombination DNA Repair Genes by HDAC Inhibition in Prostate Cancer Is Mediated through the E2F1 Transcription Factor , 2010, PloS one.

[15]  H. Kohler,et al.  Histone deacetylases 1 and 2 act in concert to promote the G1-to-S progression. , 2010, Genes & development.

[16]  James E. Bradner,et al.  Chemical Phylogenetics of Histone Deacetylases , 2010, Nature chemical biology.

[17]  G. Leclerc,et al.  Histone deacetylase inhibitors induce FPGS mRNA expression and intracellular accumulation of long-chain methotrexate polyglutamates in childhood acute lymphoblastic leukemia: implications for combination therapy , 2010, Leukemia.

[18]  Kirk C. Hansen,et al.  CBP / p300-mediated acetylation of histone H3 on lysine 56 , 2009, Nature.

[19]  J. Issa,et al.  Histone deacetylase inhibitors as anti-neoplastic agents. , 2009, Cancer letters.

[20]  J. Hardwick,et al.  Development of vorinostat: current applications and future perspectives for cancer therapy. , 2009, Cancer letters.

[21]  E. Olson,et al.  Genetic dissection of histone deacetylase requirement in tumor cells , 2009, Proceedings of the National Academy of Sciences.

[22]  S. Haggarty,et al.  HDAC2 negatively regulates memory formation and synaptic plasticity , 2009, Nature.

[23]  S. Jackson,et al.  Screen for DNA-damage-responsive histone modifications identifies H3K9Ac and H3K56Ac in human cells , 2009, The EMBO journal.

[24]  S. Armstrong,et al.  Chromatin maps, histone modifications and leukemia , 2009, Leukemia.

[25]  Tina N. Davis,et al.  HOXA9 is required for survival in human MLL-rearranged acute leukemias. , 2009, Blood.

[26]  C. Kenific,et al.  Parallel medicinal chemistry approaches to selective HDAC1/HDAC2 inhibitor (SHI-1:2) optimization. , 2009, Bioorganic & Medicinal Chemistry Letters.

[27]  Xiaobo Xia,et al.  H3K79 methylation profiles define murine and human MLL-AF4 leukemias. , 2008, Cancer cell.

[28]  E. Olson,et al.  Maintenance of cardiac energy metabolism by histone deacetylase 3 in mice. , 2008, The Journal of clinical investigation.

[29]  Darrell N. Kotton,et al.  Figure 3 , 2008 .

[30]  R. Martell,et al.  Histone deacetylase inhibitors in cancer therapy: new compounds and clinical update of benzamide-type agents. , 2008, Current topics in medicinal chemistry.

[31]  S. Hiebert,et al.  Liver‐specific deletion of histone deacetylase 3 disrupts metabolic transcriptional networks , 2008, The EMBO journal.

[32]  E. Seto,et al.  The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men , 2008, Nature Reviews Molecular Cell Biology.

[33]  Joshua Close,et al.  Exploration of the internal cavity of histone deacetylase (HDAC) with selective HDAC1/HDAC2 inhibitors (SHI-1:2). , 2008, Bioorganic & medicinal chemistry letters.

[34]  P. Atadja,et al.  The novel histone deacetylase inhibitor, LBH589, induces expression of DNA damage response genes and apoptosis in Ph- acute lymphoblastic leukemia cells. , 2007, Blood.

[35]  E. Seto,et al.  Histone deacetylases and cancer , 2007, Oncogene.

[36]  Jessica E. Bolden,et al.  Anticancer activities of histone deacetylase inhibitors , 2006, Nature Reviews Drug Discovery.

[37]  Julia Tischler,et al.  Negative and Positive Regulation of Gene Expression by Mouse Histone Deacetylase1 , 2006, Molecular and Cellular Biology.

[38]  T. Golub,et al.  Transformation from committed progenitor to leukaemia stem cell initiated by MLL–AF9 , 2006, Nature.

[39]  G. Mufti,et al.  Histone Deacetylase Inhibitors (HDI) Cause DNA Damage in Leukemia Cells: A Mechanism for Leukemia-Specific HDI-Dependent Apoptosis? , 2006, Molecular Cancer Research.

[40]  S. Schreiber,et al.  Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[41]  P. Atadja,et al.  Use of a novel histone deacetylase inhibitor to induce apoptosis in cell lines of acute lymphoblastic leukemia. , 2004, Haematologica.

[42]  Stuart L Schreiber,et al.  Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[43]  Minoru Yoshida,et al.  FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. , 2002, Cancer research.

[44]  D. O’Carroll,et al.  Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression , 2002, The EMBO journal.

[45]  P. Marks,et al.  Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. , 2000, Proceedings of the National Academy of Sciences of the United States of America.